MARKET

HUMAW

HUMAW

Humacyte Inc
NASDAQ
0.5500
+0.1201
+27.92%
Opening 13:45 05/14 EDT
OPEN
0.4900
PREV CLOSE
0.4299
HIGH
0.6500
LOW
0.4508
VOLUME
81.81K
TURNOVER
--
52 WEEK HIGH
3.470
52 WEEK LOW
0.1705
MARKET CAP
--
P/E (TTM)
-0.4382
1D
5D
1M
3M
1Y
5Y
1D
HUMACYTE INC <HUMA.O>: BENCHMARK CUTS TARGET PRICE TO $14 FROM $17
Reuters · 5h ago
Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026
Seeking Alpha · 23h ago
Humacyte Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 1d ago
Weekly Report: what happened at HUMAW last week (0505-0509)?
Weekly Report · 2d ago
HUMACYTE TO PRESENT FIRST QUARTER FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON MAY 13, 2025
Reuters · 5d ago
Weekly Report: what happened at HUMAW last week (0428-0502)?
Weekly Report · 05/05 09:15
Weekly Report: what happened at HUMAW last week (0421-0425)?
Weekly Report · 04/28 09:17
Weekly Report: what happened at HUMAW last week (0414-0418)?
Weekly Report · 04/21 09:17
More
About HUMAW
More
Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.
Recently
Symbol
Price
%Change

Webull offers Humacyte Inc stock information, including NASDAQ: HUMAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMAW stock methods without spending real money on the virtual paper trading platform.